Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
February 24, 2026Pamplona/MadridIn recruitment
D516KC00001 Clinical trial of Dato-DXd, with or without osimertinib, versus platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer with EGFR mutation
The objective of this study is to evaluate whether the drug Dato-DXd alone (monotherapy), or in combination with osimertinib, can safely enable longer disease control compared to the current standard of care (SOC) chemotherapy treatment option in patients who have failed prior treatment with osimertinib. -
February 24, 2026PamplonaIn recruitmentEarly phase
ISB 2001-101 Clinical trial of dose escalation and extended dose administration of ISB 2001 as monotherapy in participants with relapsed/refractory multiple myeloma
The purpose of the study is to test whether an experimental drug called ISB 2001 is safe and well tolerated. The study will also determine the dose(s) of ISB 2001 that can be safely administered, the amount of the drug that enters the bloodstream while participating in the study, and whether the drug can be used to treat multiple myeloma. -
February 24, 2026MadridIn recruitmentEarly phase
D702EC00001 Phase I clinical trial to investigate subcutaneous rilvegostomig in adult participants with advanced solid tumors who have previously received treatment.
The primary objective is to determine the pharmacokinetics (PK) of subcutaneous (SC) Rilvegostomig compared to intravenous (IV) Rilvegostomig 750 mg every 3 weeks (Q3W). -
February 23, 2026MadridIn recruitmentEarly phase
ZWI-ZW191-101 Phase I clinical trial to evaluate ZW191 in participants with advanced solid tumors
The primary objective is to evaluate the safety and tolerability of ZW191 and determine the DMT and DREs of ZW191 in different tumor types. -
February 23, 2026Pamplona/MadridIn recruitmentEarly phase
OZUHN-007 Clinical trial for perioperative treatment with durvalumab plus tremelimumab in patients with resectable hepatocellular carcinoma (HCC)
The main goal of this study, which includes research, is to determine whether the new cancer drug durvalumab given with tremelimumab is safe before surgery. Doctors also want to see if the study drugs cause any delays in surgery due to side effects that participants may experience. Doctors will also analyze the effect that the study drugs have on the tumor and whether the tumor recurs after the combination of the study drugs and surgery. -
February 17, 2026PamplonaIn recruitmentEarly phase
OMTX705-001 Clinical trial with OMTX705, an antibody conjugate against fibroblast activation protein, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
The objective of the study is to investigate the safety and preliminary antitumor activity of the antibody-drug conjugate OMTX705 (ADC OMTX705 linked to a cytotoxic tubulysin) in patients with advanced or metastatic cancer. -
February 17, 2026Pamplona/MadridIn recruitment
-
February 10, 2026Pamplona/MadridIn recruitment
LOXO-BTK-20030 Clinical trial of pirtobrutinib (LOXO-305) compared with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (BRUIN-CLL-314)
The objectives of this clinical trial are as follows: - To determine the response of patients with CLL/PLLC to treatment with pirtobrutinib (group A) compared to ibrutinib (group B). - To determine the duration of the beneficial effects of treatment with the study drugs (including how long patients live). - To determine safety and tolerability in group A and group B. - To determine how patients in group A fare compared to those in group B. -
February 4, 2026PamplonaIn recruitment
UCART20X22-01 Clinical trial to evaluate UCART20x22 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
This study is being conducted to determine: - the safe and tolerable dose of UCART20x22 - the efficacy of UCART20x22 in the treatment of NHLB - how long it takes for the body to eliminate UCART20x22 - how much UCART20x22 reaches the bloodstream This study will also test the safety and effectiveness of different lymphodepletion regimens for patients receiving UCART20x22. Lymphodepletion is a type of therapy that decreases the number of your T cells to make room for the UCART20x22 cells. Three dru... -
February 4, 2026Pamplona/MadridIn recruitmentEarly phase
IOV-LUN-202 Clinical trial of autologous tumor-infiltrating lymphocytes (LN-145) in patients with metastatic non-small cell lung cancer
The objective of this study is to test a new investigational treatment for participants with non-small cell lung cancer.